Thus, emerging data suggest that immunotherapy approaches aimed at increasing NK cell fitness/function/abundance should not only reduce metastasis rates and periods of progression-free survival but also positively impact tumor antigen presentation to CD8 + T cells via cDC1s, T-cell Th1 polarization and tumor immune infiltration. The gene discussed is CD8A; the disease is neoplasm.